Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneron Pharmaceuticals and Sanofi are conducting a Phase 3 clinical study titled ‘A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1).’ The study aims to evaluate the efficacy and safety of Dupilumab in treating pruritus associated with Lichen Simplex Chronicus (LSC) in adults, highlighting its potential significance in addressing this chronic skin condition.
The intervention being tested is Dupilumab, administered via subcutaneous injections. Dupilumab is an experimental drug intended to alleviate symptoms of pruritus in LSC patients, with a placebo group serving as a comparator.
This interventional study employs a randomized, parallel-group design with quadruple masking, involving participants, care providers, investigators, and outcomes assessors. The primary purpose is treatment, focusing on the therapeutic impact of Dupilumab.
The study began on November 28, 2024, with an estimated primary completion date yet to be disclosed. The latest update was submitted on August 6, 2025, indicating ongoing recruitment and progress.
This update could influence the stock performance of Regeneron Pharmaceuticals and Sanofi, as successful results may enhance investor confidence and market position. The competitive landscape in dermatological treatments may also be affected, depending on the study’s outcomes.
The study is currently ongoing, with further details available on the ClinicalTrials portal.